BRAF V600E is a recurrent driver in low-grade serous ovarian carcinoma (LGSOC) — ~30% of...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-BRAF-V600E-OVARIAN |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-OVARIAN |
| Sources | SRC-CIVIC SRC-ESMO-OVARIAN-2024 SRC-NCCN-OVARIAN-2025 |
Actionability Facts
| Biomarker | BIO-BRAF-V600E |
|---|---|
| Variant | V600E |
| Disease | DIS-OVARIAN |
| ESCAT tier | IIA |
| Recommended combinations | dabrafenib + trametinib (tissue-agnostic indication; LGSOC preferred), trametinib monotherapy (LGSOC, regardless of BRAF status — GOG 281) |
| Evidence summary | BRAF V600E is a recurrent driver in low-grade serous ovarian carcinoma (LGSOC) — ~30% of LGSOC. Tissue-agnostic FDA approval of dabrafenib + trametinib for BRAF V600E solid tumors (Subbiah et al. ROAR; Salama et al. NCI-MATCH 2020) covers ovarian. ORR ~33% in basket trials. MEK inhibitors (trametinib, binimetinib) also active in LGSOC regardless of BRAF status (MILO, GOG 281). |
Notes
ESCAT IIA — prospective basket evidence + tissue-agnostic approval. OncoKB Level 2. High-grade serous ovarian rarely BRAF V600E (<1%) — predominantly TP53-mutant; tissue-agnostic label still applies but yield is low. Reflex BRAF testing for LGSOC recommended.
Used By
No reverse references found in the YAML corpus.